Table 2 Demographics and baseline clinical characteristics
From: The impact of integrated disease management in high-risk COPD patients in primary care
All subjects (n = 168) | Integrated disease management (n = 84) | Usual care (n = 84) | |
|---|---|---|---|
Sex, female | 90 (53.6%) | 50 (59.5%) | 40 (47.6%) |
Age, years | 68.2 (9.7) | 68.6 (9.6) | 67.9 (9.8) |
Caucasian | 164 (97.6%) | 82 (97.6%) | 82 (97.6%) |
BMI (kg/m2) | 27.3 (6.3) | 27.9 (6.9) | 26.8 (5.6) |
FEV1 | |||
Pre-bronchodilator—litres | 1.39 (0.54) | 1.38 (0.55) | 1.40 (0.53) |
Pre-bronchodilator—% predicted | 52.8 (14.5) | 53.6 (14.2) | 52.0 (14.7) |
Post-bronchodilator—litres | 1.43 (0.52) | 1.42 (0.54) | 1.43 (0.51) |
Post-bronchodilator—% predicted | 54.3 (14.6) | 55.5 (14.5) | 53.2 (14.7) |
FEV1/FVC ratio | |||
Post-bronchodilator | 54.6 (11.1) | 55.6 (11.8) | 53.6 (10.4) |
Current smoker | 81 (48.2%) | 33 (39.3%) | 48 (57.1%) |
Baseline MRC score (range 0–5) | 2.9 (0.9) | 3.0 (0.9) | 2.8 (0.8) |
GOLD stage | |||
(a) A | 4 (2.4%) | 3 (3.6%) | 1 (1.2%) |
(b) B | 30 (17.9%) | 12 (14.3%) | 18 (21.4%) |
(c) C | 4 (2.4%) | 0 (0.0%) | 4 (4.8%) |
(d) D | 130 (77.4%) | 69 (82.1%) | 61 (72.6% |
Baseline CAT score (range 0–40) | 21.1 (7.2) | 22.8 (7.2) | 19.5 (6.9) |
Severe exacerbation (prior year: prednisone and/or antibiotics) | 126 (75.0%) | 63 (75.0%) | 63 (75.0%) |
COPD health service use prior year | |||
(a) Number of urgent physician visits | 2.1 (1.9) | 2.4 (2.1) | 1.9 (1.5) |
Any urgent physician visit | 141 (83.9%) | 72 (85.7%) | 69 (82.1%) |
(b) Number of ED visits | 0.5 (0.9) | 0.6 (0.8) | 0.5 (1.0) |
Any ED visit | 59 (35.1%) | 36 (42.9%) | 23 (27.4%) |
(c) Number of hospitalizations | 0.3 (0.6) | 0.3 (0.7) | 0.3 (0.5) |
Any hospitalization | 34 (20.2%) | 14 (16.7%) | 20 (23.8%) |
